Shenzhen Salubris Pharmaceuticals Co., Ltd.

This product is a second-generation cephalosporin for intravenous or intramuscular injection. It has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci. Its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and group B streptococci, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Fecal Streptococcus, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, group B streptococci and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.

It has a broad spectrum of antibacterial activity against Gram-positive and Gram-negative bacteria, especially against Escherichia coli, Klebsiella, Haemophilus influenzae, Proteus and Bacteroides fragilis. Its mechanism of action is that it shows a strong affinity for penicillin-binding protein, which is the usual point of action of beta-lactam antibiotics, inhibits cell wall synthesis, binds to peptidoglycan, inhibits the binding of peptidoglycan to lipoprotein to promote bacteriolysis, and shows a strong bactericidal effect in a short time. This product shows antibacterial effect on bacteria during the proliferation period and the early stage of the stable period, and has a bactericidal effect at concentrations lower than the MIC, and lyses bacteria in a short time. The antibacterial effect in vivo is stronger than the prediction of MIC.

This product belongs to the third generation of cephalosporin, has a broad-spectrum antibacterial effect, and is stable to β-lactamase produced by most bacteria. This product is mainly effective against a variety of G and G- bacteria and anaerobic bacteria. It has an immunomodulatory effect, that is, it can be used as a biological response modifier (BRM) to increase CD4 in the body, thereby increasing the CD4/CD8 value and playing a synergistic bactericidal effect. The mechanism of action of this product is that this product achieves a bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides.

This product belongs to the third generation of cephalosporin, has a broad-spectrum antibacterial effect, and is stable to β-lactamase produced by most bacteria. This product is mainly effective against a variety of G and G- bacteria and anaerobic bacteria. It has an immunomodulatory effect, that is, it can be used as a biological response modifier (BRM) to increase CD4 in the body, thereby increasing the CD4/CD8 value and playing a synergistic bactericidal effect. The mechanism of action of this product is that this product achieves a bactericidal effect by inhibiting the biosynthesis of bacterial cell wall mucopeptides.

This product is a platelet aggregation inhibitor that can selectively inhibit the binding of ADP to platelet receptors, and then inhibit the activation of ADP and glycoprotein GPⅡb/Ⅲa complex, thereby inhibiting platelet aggregation. This product can also inhibit platelet aggregation caused by non-ADP, and does not affect the activity of phosphodiesterase. This product affects the life of platelets by irreversibly changing platelet ADP receptors.